A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations

Trial Profile

A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Neratinib (Primary) ; Temsirolimus
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 31 May 2018 Status changed from active, no longer recruiting to completed.
    • 23 Jan 2018 This study is completed in France (06-Oct-2017).
    • 06 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top